PHAT Articles, Phathom Pharmaceuticals Inc.

Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase since last quarterly report Ne...

Management to host conference call on Thursday, May 9, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Phathom Ph...

U.S. stocks were mostly lower, with the Nasdaq Composite falling more than 200 points on Tuesday. Shares of Walmart Inc. (NYSE: WMT) rose in today...

FLORHAM PARK, N.J., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on develo...

Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT), raising the price targ...

Amendment provides more favorable terms including a 14-month extension of the interest-only period and maturity date until December 2027 Up to an...

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) (...

Phathom Pharmaceuticals Inc (NASDAQ: PHAT) shares are trading higher Monday after the company announced FDA approval of its reformulated vonop...

FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on develo...

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended not buying ChargePoint Holdings, Inc. (NYSE: CHPT) because it's...